Emergent Biosolutions Lowered to “Neutral” at Zacks (EBS)
Emergent Biosolutions (NYSE:EBS) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report released on Tuesday. They currently have a $25.10 price objective on the stock. Zacks‘s target price points to a potential upside of 8.85% from the company’s current price.
Emergent Biosolutions (NYSE:EBS) traded up 0.30% during mid-day trading on Tuesday, hitting $23.13. 366,601 shares of the company’s stock traded hands. Emergent Biosolutions has a one year low of $15.11 and a one year high of $28.48. The stock’s 50-day moving average is $22.18 and its 200-day moving average is $24.19. The company has a market cap of $865.3 million and a price-to-earnings ratio of 45.13.
Emergent Biosolutions (NYSE:EBS) last released its earnings data on Thursday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.14) by $0.41. The company had revenue of $53.90 million for the quarter, compared to the consensus estimate of $57.30 million. During the same quarter last year, the company posted ($0.22) earnings per share. Emergent Biosolutions’s revenue was up 25.1% compared to the same quarter last year. On average, analysts predict that Emergent Biosolutions will post $1.16 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on EBS. Analysts at Summer Street initiated coverage on shares of Emergent Biosolutions in a research note on Thursday, May 15th. They set a “buy” rating and a $35.00 price target on the stock. Analysts at TheStreet downgraded shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Monday, May 12th.
Emergent BioSolutions Inc is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.